You are here

Noninterventional Study in Bipolar Disorder and Schizophrenia With Zeldox

Last updated on April 10, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bipolar Disorder, Schizophrenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Manic and mixed episodes of up to moderate severity in patients with type I and II
bipolar disorder and schizophrenia; either first diagnosed or repeated episodes.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with a history of hypersensitivity to Ziprasidone.

- Previous insufficiency of the Ziprasidone´s treatment.

- The break of the previous therapeutic condition.

NCT00538629
Pfizer
Completed
Noninterventional Study in Bipolar Disorder and Schizophrenia With Zeldox

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Pain, Depression, Anxiety Disorder
NCT00241397
All Genders
18+
Years
Multiple Sites
Obsessive Compulsive Disorder
NCT01302080
All Genders
6+
Years
Multiple Sites
Panic Disorder, Depression
NCT00605865
All Genders
Noninterventional Study in Bipolar Disorder and Schizophrenia With Zeldox
Noninterventional Study (NIS) in Patients With Bipolar Disorder (Manic or Mixed Episodes) and Schizophrenia Undergoing Treatment With Zeldox
Investigation of the impact of Zeldox on metabolic parameters in patients with bipolar disorder or with schizophrenia and the impact of the treatment with quality of life.
Observational survey consecutive patient sampling.
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Psychiatric outpatients
  • Bipolar Disorder
  • Schizophrenia
Other: no intervention
No intervention
  • Schizophrenia
    Patients with schizophrenia
    Intervention: Other: no intervention
  • Bipolar disorder
    Patients with bipolar disorder
    Intervention: Other: no intervention
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
471
April 2008
April 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Manic and mixed episodes of up to moderate severity in patients with type I and II bipolar disorder and schizophrenia; either first diagnosed or repeated episodes.

Exclusion Criteria:

  • Patients with a history of hypersensitivity to Ziprasidone.
  • Previous insufficiency of the Ziprasidone´s treatment.
  • The break of the previous therapeutic condition.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00538629
A1281171
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure, Pfizer Inc
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2009

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now